Advanced
  Home Compare Reports

Comparison with Similar Reports

Therapeutic Drug Monitoring Market by Product (Consumables, Equipment-Immunoassay Analyzers, Chromatography & MS Detectors, Clinical Chemistry Analyze...

Publisher:        MarketsandMarkets

# of Pages:        284

Rating: 

1 User License $4,950

Publication Date:  February, 2022

Price:       $4,950 / User License




1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.2.1 INCLUSIONS & EXCLUSIONS 41
1.3 MARKET SCOPE 42
1.3.1 MARKETS COVERED 42
1.3.2 YEARS COVERED FOR THE STUDY 43
1.4 CURRENCY 43
1.5 LIMITATIONS 43
1.6 MARKET STAKEHOLDERS 44
1.7 SUMMARY OF CHANGES 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Secondary sources 47
2.1.2 PRIMARY DATA 47
FIGURE 2 PRIMARY SOURCES 47
2.1.2.1 Key data from primary sources 48
2.1.2.2 Key industry insights 49
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 50
2.2 MARKET SIZE ESTIMATION 50
FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION: THERMO FISHER SCIENTIFIC 51
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 51
2.2.1 GROWTH FORECAST 52
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 7 TOP-DOWN APPROACH 53
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 54
FIGURE 8 DATA TRIANGULATION METHODOLOGY 54
2.4 MARKET SHARE ANALYSIS 55
2.5 ASSUMPTIONS FOR THE STUDY 55
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 56
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 57
2.7 RISK ASSESSMENT 57
TABLE 1 RISK ASSESSMENT 57
2.8 COVID-19 HEALTH ASSESSMENT 58
2.9 COVID-19 ECONOMIC ASSESSMENT 58
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 59
3 EXECUTIVE SUMMARY 61
FIGURE 11 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 61
FIGURE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 62
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2021 VS. 2026 (USD MILLION) 62
FIGURE 14 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 63
FIGURE 15 GEOGRAPHIC SNAPSHOT OF THE GLOBAL THERAPEUTIC
DRUG MONITORING MARKET 63
4 PREMIUM INSIGHTS 65
4.1 THERAPEUTIC DRUG MONITORING MARKET OVERVIEW 65
FIGURE 16 RISING PREFERENCE FOR PRECISION MEDICINE TO DRIVE THE TDM MARKET 65
4.2 THERAPEUTIC DRUG MONITORING MARKET, BY TYPE 65
FIGURE 17 CONSUMABLE PRODUCTS TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021 65
4.3 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 66
FIGURE 18 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC MARKET IN
2021-2026 66
4.4 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET 67
FIGURE 19 CHINA TO REGISTER THE HIGHEST CAGR OVER THE FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 20 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 69
5.2.1.1 Importance of TDM in organ transplant procedures 69
FIGURE 21 NUMBER OF DECEASED DONORS AND TRANSPLANTS IN THE UK (APRIL 1, 2017–MARCH 31, 2021) 69
5.2.1.2 Use of TDM across various therapeutic fields 70
TABLE 2 CLASSES OF DRUGS THAT REQUIRE MONITORING 70
5.2.1.3 Increasing preference for precision medicine 71
5.2.1.4 Growing focus on R&D related to TDM 71
FIGURE 22 NUMBER OF RESEARCH PUBLICATIONS ON THERAPEUTIC DRUG MONITORING (2015–2020) 71
5.2.1.5 Technological advancements 72
5.2.2 RESTRAINTS 72
5.2.2.1 Requirement of high capital investments 72
5.2.2.2 Reluctance of small hospitals to offer TDM services 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing adoption in the treatment of autoimmune diseases 73
5.2.4 CHALLENGES 73
5.2.4.1 Alternatives to conventional TDM 73
5.2.4.2 Operational barriers faced in conducting TDM tests 74
5.3 COVID-19 IMPACT ON THE THERAPEUTIC DRUG MONITORING MARKET 74
5.4 RANGES/SCENARIOS 75
5.4.1 THERAPEUTIC DRUG MONITORING MARKET 75
FIGURE 23 PESSIMISTIC SCENARIO 75
FIGURE 24 OPTIMISTIC SCENARIO 75
FIGURE 25 REALISTIC SCENARIO 76
5.5 VALUE CHAIN ANALYSIS 76
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 77
5.6 SUPPLY CHAIN ANALYSIS 77
FIGURE 27 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY FOR PROMINENT COMPANIES 79
5.7 PORTER’S FIVE FORCES ANALYSIS 80
5.7.1 THREAT OF NEW ENTRANTS 80
5.7.2 INTENSITY OF COMPETITIVE RIVALRY 80
5.7.3 BARGAINING POWER OF BUYERS 80
5.7.4 BARGAINING POWER OF SUPPLIERS 80
5.7.5 THREAT OF SUBSTITUTES 80
5.8 REGULATORY LANDSCAPE 81
5.9 PATENT ANALYSIS 82
5.10 PRICING ANALYSIS 83
TABLE 3 PRICE RANGE FOR THERAPEUTIC DRUG MONITORING 83
5.11 TRADE ANALYSIS 83
TABLE 4 IMPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL AND CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION) 83
TABLE 5 EXPORT DATA FOR INSTRUMENTS AND APPLIANCES USED IN PHYSICAL
AND CHEMICAL ANALYSIS, BY COUNTRY, BY COUNTRY,
2016–2020 (USD MILLION) 83
5.12 ECOSYSTEM ANALYSIS 84
5.12.1 ROLE IN ECOSYSTEM 85
FIGURE 28 KEY PLAYERS IN THE THERAPEUTIC DRUG MONITORING 85
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 86
5.13.1 REVENUE SHIFT AND REVENUE POCKETS FOR THERAPEUTIC DRUG MONITORING MARKET 86
5.13.2 REVENUE SHIFT FOR THERAPEUTIC DRUG MONITORING 86
 
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT 87
6.1 INTRODUCTION 88
TABLE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 88
TABLE 7 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 88
6.2 CONSUMABLES 88
6.2.1 REPEAT PURCHASE AND HIGH USAGE OF CONSUMABLES
DRIVE MARKET GROWTH 88
TABLE 8 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2016–2020 (USD MILLION) 89
TABLE 9 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 2021–2026 (USD MILLION) 89
6.3 EQUIPMENT 89
TABLE 10 DRUGS MONITORED USING ANALYTICAL EQUIPMENT 89
TABLE 11 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2016–2020 (USD MILLION) 90
TABLE 12 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE,
2021–2026 (USD MILLION) 90
TABLE 13 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2016–2020 (USD MILLION) 91
TABLE 14 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION,
2021–2026 (USD MILLION) 91
6.3.1 IMMUNOASSAY ANALYZERS 91
6.3.1.1 The high efficiency of immunoassay analyzers has ensured
end-user demand 91
TABLE 15 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2016–2020 (USD MILLION) 92
TABLE 16 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 2021–2026 (USD MILLION) 92
6.3.2 CHROMATOGRAPHY & MS DETECTORS 92
6.3.2.1 Technological advancements have propelled the growth of the segment 92
TABLE 17 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY &
MS DETECTORS, BY REGION, 2016–2020 (USD MILLION) 93
TABLE 18 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY &
MS DETECTORS, BY REGION, 2021–2026 (USD MILLION) 93
6.3.3 CLINICAL CHEMISTRY ANALYZERS 93
6.3.3.1 Automation to raise preference for clinical chemistry analyzers 93
TABLE 19 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2016–2020 (USD MILLION) 94
TABLE 20 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2021–2026 (USD MILLION) 94
6.4 IMPACT OF COVID-19 ON THE TDM MARKET, BY PRODUCT 94
 
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY 95
7.1 INTRODUCTION 96
TABLE 21 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 96
TABLE 22 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 96
7.2 IMMUNOASSAYS 96
TABLE 23 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 97
TABLE 24 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 97
TABLE 25 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 97
TABLE 26 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 98
7.2.1 CHEMILUMINESCENCE IMMUNOASSAYS 98
7.2.1.1 Rapid detection time and good specificity support the
growth of the segment 98
TABLE 27 CLIA SYSTEMS AVAILABLE IN THE MARKET 98
TABLE 28 LIST OF COMPOUNDS ANALYZED BY CHEMILUMINESCENCE IMMUNOASSAY 99
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 100
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 100
7.2.2 FLUORESCENCE IMMUNOASSAYS 100
7.2.2.1 High operability and better sensitivity of FIAs to drive market growth 100
TABLE 31 LIST FOR COMPOUNDS ANALYZED BY FLUORESCENCE POLARIZATION IMMUNOASSAYS 101
TABLE 32 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 101
TABLE 33 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 102
7.2.3 COLORIMETRIC IMMUNOASSAYS 102
7.2.3.1 Demand for colorimetric immunoassays to decline due to the rising preference for advanced equipment 102
TABLE 34 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION,
2016–2020 (USD MILLION) 102
TABLE 35 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION,
2021–2026 (USD MILLION) 103
7.2.4 RADIOIMMUNOASSAYS 103
7.2.4.1 High sensitivity in drug detection applications supports the market for radioimmunoassays 103
TABLE 36 LIST OF COMPOUNDS ANALYZED BY RADIOIMMUNOASSAYS 103
TABLE 37 RADIOIMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 104
TABLE 38 RADIOIMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 105
7.2.5 OTHER IMMUNOASSAYS 105
TABLE 39 OTHER IMMUNOASSAYS MARKET, BY REGION, 2016–2020 (USD MILLION) 105
TABLE 40 OTHER IMMUNOASSAYS MARKET, BY REGION, 2021–2026 (USD MILLION) 106
7.3 CHROMATOGRAPHY-MS 106
TABLE 41 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2016–2020 (USD MILLION) 106
TABLE 42 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS,
BY TYPE, 2021–2026 (USD MILLION) 107
7.3.1 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 107
7.3.1.1 High accuracy supports the demand for LC-MS 107
TABLE 43 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION) 107
TABLE 44 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION) 108
7.3.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY 108
7.3.2.1 Drawbacks of GC-MS challenge market growth 108
TABLE 45 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2016–2020 (USD MILLION) 108
TABLE 46 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 2021–2026 (USD MILLION) 109
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG 110
8.1 INTRODUCTION 111
TABLE 47 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2020 (USD MILLION) 111
TABLE 48 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2021–2026 (USD MILLION) 111
8.2 ANTIEPILEPTIC DRUGS 112
8.2.1 HIGH COMPLEXITY AND HETEROGENEITY OF EPILEPSY TO DRIVE THE GROWTH OF THE SEGMENT 112
TABLE 49 LIMITATIONS OF TDM OF NEWER ANTIEPILEPTIC DRUGS 112
TABLE 50 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 113
TABLE 51 ANTIEPILEPTIC DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 113
8.3 ANTIARRHYTHMIC DRUGS 113
8.3.1 INCREASING INCIDENCE OF HEART DISORDERS
TO SUPPORT SEGMENT GROWTH 113
TABLE 52 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 114
TABLE 53 ANTIARRHYTHMIC DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 114
8.4 IMMUNOSUPPRESSANT DRUGS 114
8.4.1 IMMUNOSUPPRESSANT DEMAND HAS RISEN DUE TO AN INCREASE IN ORGAN TRANSPLANTATION PROCEDURES 114
TABLE 54 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 115
TABLE 55 IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 115
8.5 ANTIBIOTIC DRUGS 116
8.5.1 TECHNOLOGICAL ADVANCEMENTS TO PROPEL THE DEMAND FOR ANTIBIOTIC DRUG MONITORING 116
TABLE 56 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 116
TABLE 57 ANTIBIOTIC DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 116
8.6 BRONCHODILATOR DRUGS 117
8.6.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES WILL ENSURE DEMAND FOR BRONCHODILATOR DRUG MONITORING 117
TABLE 58 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 117
TABLE 59 BRONCHODILATOR DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 117
8.7 PSYCHOACTIVE DRUGS 118
8.7.1 RISING CASES OF MENTAL ILLNESS TO DRIVE MARKET GROWTH 118
TABLE 60 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 118
TABLE 61 PSYCHOACTIVE DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 118
8.8 OTHER DRUGS 119
TABLE 62 OTHER DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 119
TABLE 63 OTHER DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 119
8.9 IMPACT OF COVID-19 ON THE TDM MARKET, BY CLASS OF DRUG 120
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER 121
9.1 INTRODUCTION 122
TABLE 64 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 122
TABLE 65 THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 122
9.2 HOSPITAL LABORATORIES 123
9.2.1 HOSPITAL LABS HOLD THE LARGEST SHARE OF THE END-USER MARKET 123
TABLE 66 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016–2020 (USD MILLION) 123
TABLE 67 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 123
9.3 COMMERCIAL & PRIVATE LABORATORIES 124
9.3.1 EXTENSIVE TEST MENUS OF COMMERCIAL & PRIVATE LABS SUPPORT DEMAND FOR THEIR SERVICES 124
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2016–2020 (USD MILLION) 124
TABLE 69 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL & PRIVATE LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 124
9.4 OTHER END USERS 125
TABLE 70 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY REGION, 2016–2020 (USD MILLION) 125
TABLE 71 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS,
BY REGION, 2021–2026 (USD MILLION) 125
9.5 IMPACT OF COVID-19 ON THE TDM MARKET, BY END USER 125
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION 126
10.1 INTRODUCTION 127
TABLE 72 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2016–2020 (USD MILLION) 127
TABLE 73 THERAPEUTIC DRUG MONITORING MARKET, BY REGION,
2021–2026 (USD MILLION) 127
10.2 NORTH AMERICA 128
FIGURE 29 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARK ET SNAPSHOT 129
TABLE 74 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2016–2020 (USD MILLION) 130
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 2021–2026 (USD MILLION) 130
TABLE 76 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2016–2020 (USD MILLION) 130
TABLE 77 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2021–2026 (USD MILLION) 130
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION) 131
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION) 131
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 131
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 132
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 132
TABLE 83 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 132
TABLE 84 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 133
TABLE 85 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 133
TABLE 86 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 133
TABLE 87 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 134
TABLE 88 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION) 134
TABLE 89 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION) 134
10.2.1 US 135
10.2.1.1 Awareness regarding precision medicine to propel the
TDM market in the US 135
TABLE 90 NUMBER OF TESTS COVERED BY MEDICARE FOR EACH DRUG CLASS 135
TABLE 91 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 136
TABLE 92 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 136
TABLE 93 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 136
TABLE 94 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 136
TABLE 95 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 137
TABLE 96 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 137
TABLE 97 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 137
TABLE 98 US: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 138
TABLE 99 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2020 (USD MILLION) 138
TABLE 100 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2021–2026 (USD MILLION) 138
TABLE 101 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 139
TABLE 102 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 139
10.2.2 CANADA 139
10.2.2.1 Availability of funding for research to offer growth opportunities in the Canadian market 139
TABLE 103 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 140
TABLE 104 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 140
TABLE 105 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 141
TABLE 106 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 141
TABLE 107 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2020 (USD MILLION) 141
TABLE 108 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2021–2026 (USD MILLION) 142
TABLE 109 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 142
TABLE 110 CANADA: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 142
TABLE 111 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 143
TABLE 112 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 143
TABLE 113 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 143
TABLE 114 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 144
10.3 EUROPE 144
TABLE 115 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2016–2020 (USD MILLION) 144
TABLE 116 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 145
TABLE 117 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 145
TABLE 118 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 145
TABLE 119 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2016–2020 (USD MILLION) 146
TABLE 120 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 2021–2026 (USD MILLION) 146
TABLE 121 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 146
TABLE 122 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 147
TABLE 123 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2020 (USD MILLION) 147
TABLE 124 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2021–2026 (USD MILLION) 147
TABLE 125 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 148
TABLE 126 EUROPE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 148
TABLE 127 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 148
TABLE 128 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 149
TABLE 129 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 149
TABLE 130 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 149
10.3.1 GERMANY 150
10.3.1.1 Prevalence of chronic medical conditions such as cancer and diabetes will support market growth in Germany 150
TABLE 131 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 150
TABLE 132 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 151
TABLE 133 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 151
TABLE 134 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 151
TABLE 135 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2020 (USD MILLION) 152
TABLE 136 GERMANY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2021–2026 (USD MILLION) 152
TABLE 137 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 152
TABLE 138 GERMANY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 153
TABLE 139 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 153
TABLE 140 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 153
TABLE 141 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2016–2020 (USD MILLION) 154
TABLE 142 GERMANY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 2021–2026 (USD MILLION) 154
10.3.2 ITALY 154
10.3.2.1 Rising incidences of cancer to drive demand for TDM in Italy 154
TABLE 143 ITALY: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 155
TABLE 144 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 155
TABLE 145 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 155
TABLE 146 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 156
TABLE 147 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 156
TABLE 148 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 156
TABLE 149 ITALY: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 157
TABLE 150 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 157
TABLE 151 ITALY: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 157
TABLE 152 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 158
TABLE 153 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 158
TABLE 154 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 158
TABLE 155 ITALY: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 159
10.3.3 FRANCE 159
10.3.3.1 Awareness regarding the benefits of TDM to accelerate its demand across various therapeutic applications 159
TABLE 156 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 160
TABLE 157 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 160
TABLE 158 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2016–2020 (USD MILLION) 160
TABLE 159 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 160
TABLE 160 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2020 (USD MILLION) 161
TABLE 161 FRANCE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2021–2026 (USD MILLION) 161
TABLE 162 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 161
TABLE 163 FRANCE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 162
TABLE 164 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 162
TABLE 165 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 162
TABLE 166 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 163
TABLE 167 FRANCE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 163
10.3.4 SPAIN 163
10.3.4.1 Adoption of technologically advanced immunoassays has boosted the market in Spain 163
TABLE 168 SPAIN: CANCER INCIDENCE, BY TYPE, 2018 VS. 2025 164
TABLE 169 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 164
TABLE 170 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 164
TABLE 171 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 165
TABLE 172 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 165
TABLE 173 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2016–2020 (USD MILLION) 165
TABLE 174 SPAIN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET,
BY TYPE, 2021–2026 (USD MILLION) 166
TABLE 175 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 166
TABLE 176 SPAIN: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 166
TABLE 177 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 167
TABLE 178 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 167
TABLE 179 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 168
TABLE 180 SPAIN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 168
10.3.5 UK 168
10.3.5.1 Increasing cases of chronic diseases to drive the growth of the TDM market 168
TABLE 181 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 169
TABLE 182 UK: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 169
TABLE 183 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 170
TABLE 184 UK: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 170
TABLE 185 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 170
TABLE 186 UK: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 187 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 171
TABLE 188 UK: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 171
TABLE 189 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2016–2020 (USD MILLION) 172
TABLE 190 UK: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG,
2021–2026 (USD MILLION) 172
TABLE 191 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 172
TABLE 192 UK: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 173
10.3.6 REST OF EUROPE 173
TABLE 193 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2016–2020 (USD MILLION) 173
TABLE 194 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT,
2021–2026 (USD MILLION) 173
TABLE 195 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2016–2020 (USD MILLION) 174
TABLE 196 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 174
TABLE 197 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2016–2020 (USD MILLION) 174
TABLE 198 ROE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 2021–2026 (USD MILLION) 175
TABLE 199 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2016–2020 (USD MILLION) 175
TABLE 200 ROE: THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY-MS, BY TYPE, 2021–2026 (USD MILLION) 175
TABLE 201 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2016–2020 (USD MILLION) 176
TABLE 202 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2021–2026 (USD MILLION) 176
TABLE 203 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2016–2020 (USD MILLION) 177
TABLE 204 ROE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER,
2021–2026 (USD MILLION) 177

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127